Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | NSCLC | Primary research

Emodin regulates cell cycle of non-small lung cancer (NSCLC) cells through hyaluronan synthase 2 (HA2)-HA-CD44/receptor for hyaluronic acid-mediated motility (RHAMM) interaction-dependent signaling pathway

Authors: Mingzhu Li, Shengbo Jin, Yang Cao, Jian Xu, Shendong Zhu, Zheng Li

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Background

Non-small cell lung cancers (NSCLC) account for most cases of lung cancer. More effort is needed to research new drug and combination therapies for this disease. An anthraquinone derivative, emodin shows anticancer potency. We hypothesis that emodin suppresses lung cancer cells through hyaluronan (HA) synthase 2-HA-CD44/receptor for hyaluronic acid-mediated motility (RHAMM) interaction-dependent signaling pathway mediated cell cycle regulation.

Methods

We tested the effect of emodin on viability, apoptosis, and HA secretion of 5 NSCLC cell lines. We used NSCLC cells A549 for two rounds of knockdown study: (1) knocking down either the synthases (HAS2 and HAS3) or the receptors (CD44 and RHAMM); (2) knocking down either HAS2 or HAS3. Then determined the effect of emodin on viability, HA secretion, cell cycle, and expression of cyclin proteins.

Results

Emodin suppressed viability and HA secretion of all 5 NSCLC cell lines except for HA secretion of H460. Emodin had a slight apoptosis induction effect on all cell lines and was not different among cell lines. The knockdown of either the synthases or the receptors blocked emodin effects on viability while the knockdown of HAS2 block emodin effects but not HAS3. Emodin increased cells in the G1/G0 phase, and decreased cells in the S and G2/M phase by down-regulating cyclin A and B and up-regulating cyclin C, D, and E. HAS2 knockdown blocked the effects of emodin on the cell cycle.

Conclusions

This study demonstrated that emodin regulates the cell cycle of NSCLC cells through the HAS2-HA-CD44/RHAMM interaction-dependent signaling pathway.
Literature
1.
2.
Skřičková J, Kadlec B, Venclíček O, Merta Z. Lung cancer. Casopis Lekaru Ceskych. 2018;157(5):226–36.PubMed
3.
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54.PubMedCrossRef
4.
Liu H, Xiong Y, Wang H, Yang L, Wang C, Liu X, Wu Z, Li X, Ou L, Zhang R, et al. Effects of water extract from epimedium on neuropeptide signaling in an ovariectomized osteoporosis rat model. J Ethnopharmacol. 2018;221:126–36.PubMedCrossRef
5.
Liu H, Xiong Y, Zhu X, Gao H, Yin S, Wang J, Chen G, Wang C, Xiang L, Wang P, et al. Icariin improves osteoporosis, inhibits the expression of PPARgamma, C/EBPalpha, FABP4 mRNA, N1ICD and jagged1 proteins, and increases Notch2 mRNA in ovariectomized rats. Exp Ther Med. 2017;13(4):1360–8.PubMedPubMedCentralCrossRef
6.
Wu Z, Ou L, Wang C, Yang L, Wang P, Liu H, Xiong Y, Sun K, Zhang R, Zhu X. Icaritin induces MC3T3-E1 subclone14 cell differentiation through estrogen receptor-mediated ERK1/2 and p38 signaling activation. Biomed Pharmacother. 2017;94:1–9.PubMedCrossRef
7.
Chen G, Wang C, Wang J, Yin S, Gao H, Xiang LU, Liu H, Xiong Y, Wang P, Zhu X, et al. Antiosteoporotic effect of icariin in ovariectomized rats is mediated via the Wnt/beta-catenin pathway. Exp Ther Med. 2016;12(1):279–87.PubMedPubMedCentralCrossRef
8.
Haixia W, Shu M, Li Y, Panpan W, Kehuan S, Yingquan X, Hengrui L, Xiaoguang L, Zhidi W, Ling O. Effectiveness associated with different therapies for senile osteopo-rosis: a network Meta-analysis. J Tradit Chin Med. 2020;40(1):17–27.
9.
Yang Y-C, Lim M-Y, Lee H-S. Emodin isolated from Cassia obtusifolia (Leguminosae) seed shows larvicidal activity against three mosquito species. J Agric Food Chem. 2003;51(26):7629–31.PubMedCrossRef
10.
Naqvi S, Ullah M, Hadi S. DNA degradation by aqueous extract of Aloe vera in the presence of copper ions. Indian J Biochem Biophys. 2010;47(3):161–5.PubMed
11.
Lee M-H, Kao L, Lin C-C. Comparison of the antioxidant and transmembrane permeative activities of the different Polygonum cuspidatum extracts in phospholipid-based microemulsions. J Agric Food Chem. 2011;59(17):9135–41.PubMedCrossRef
12.
Wang J-B, Zhao H-P, Zhao Y-L, Jin C, Liu D-J, Kong W-J, Fang F, Zhang L, Wang H-J, Xiao X-H. Hepatotoxicity or hepatoprotection? Pattern recognition for the paradoxical effect of the Chinese herb Rheum palmatum L in treating rat liver injury. PloS one. 2011;6:9.
13.
Wang M, Zhao R, Wang W, Mao X, Yu J. Lipid regulation effects of Polygoni Multiflori Radix, its processed products and its major substances on steatosis human liver cell line L02. J Ethnopharmacol. 2012;139(1):287–93.PubMedCrossRef
14.
Shrimali D, Shanmugam MK, Kumar AP, Zhang J, Tan BK, Ahn KS, Sethi G. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 2013;341(2):139–49.PubMedCrossRef
15.
Wei W-T, Lin S-Z, Liu D-L, Wang Z-H. The distinct mechanisms of the antitumor activity of emodin in different types of cancer. Oncol Rep. 2013;30(6):2555–62.PubMedCrossRef
16.
Zhang X, Chen Y, Zhang T, Zhang Y. Inhibitory effect of emodin on human hepatoma cell line SMMC-7721 and its mechanism. Afr Health Sci. 2015;15(1):97–100.PubMedPubMedCentralCrossRef
17.
Itano N, Sawai T, Yoshida M, Lenas P, Yamada Y, Imagawa M, Shinomura T, Hamaguchi M, Yoshida Y, Ohnuki Y, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem. 1999;274(35):25085–92.PubMedCrossRef
18.
19.
Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem. 2002;277(7):4589–92.PubMedCrossRef
20.
21.
Li XQ, Thonar EJ, Knudson W. Accumulation of hyaluronate in human lung carcinoma as measured by a new hyaluronate ELISA. Connect Tissue Res. 1989;19(2–4):243–53.PubMedCrossRef
22.
Pirinen R, Tammi R, Tammi M, Hirvikoski P, Parkkinen JJ, Johansson R, Böhm J, Hollmén S, Kosma VM. Prognostic value of hyaluronan expression in non-small-cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer. 2001;95(1):12–7.PubMedCrossRef
23.
Ko YH, Won HS, Jeon EK, Hong SH, Roh SY, Hong YS, Byun JH, Jung CK, Kang JH. Prognostic significance of CD44s expression in resected non-small cell lung cancer. BMC Cancer. 2011;11:340.PubMedPubMedCentralCrossRef
24.
Wimmel A, Kogan E, Ramaswamy A, Schuermann M. Variant expression of CD44 in preneoplastic lesions of the lung. Cancer. 2001;92(5):1231–6.PubMedCrossRef
25.
Song JM, Im J, Nho RS, Han YH, Upadhyaya P, Kassie F. Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells. Mol Carcinogenesis. 2019;58(3):321–33.CrossRef
26.
Li X, Peng B, Zhu X, Wang P, Xiong Y, Liu H, Sun K, Wang H, Ou L, Wu Z, et al. Changes in related circular RNAs following ERbeta knockdown and the relationship to rBMSC osteogenesis. Biochem Biophys Res Commun. 2017;493(1):100–7.PubMedCrossRef
27.
Li R, Xiao C, Liu H, Huang Y, Dilger JP, Lin J. Effects of local anesthetics on breast cancer cell viability and migration. BMC Cancer. 2018;18(1):666.PubMedPubMedCentralCrossRef
28.
Liu X, Liu H, Xiong Y, Yang L, Wang C, Zhang R, Zhu X. Postmenopausal osteoporosis is associated with the regulation of SP, CGRP, VIP, and NPY. Biomed Pharmacother. 2018;104:742–50.PubMedCrossRef
29.
Liu H, Dilger JP, Lin J. Effects of local anesthetics on cancer cells. Pharmacol Ther. 2020;212:107558.PubMedCrossRef
30.
Foster KA, Oster CG, Mayer MM, Avery ML, Audus KL. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp Cell Res. 1998;243(2):359–66.PubMedCrossRef
31.
Tang ZH, Jiang XM, Guo X, Fong CM, Chen X, Lu JJ. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line. Oncotarget. 2016;7(49):81598–610.PubMedPubMedCentralCrossRef
32.
Guo W, Xie L, Zhao L, Zhao Y. mRNA and microRNA expression profiles of radioresistant NCI-H520 non-small cell lung cancer cells. Mol Med Rep. 2015;12(2):1857–67.PubMedPubMedCentralCrossRef
33.
Giaccone G, Battey J, Gazdar AF, Oie H, Draoui M, Moody TW. Neuromedin B is present in lung cancer cell lines. Cancer Res. 1992;52(9 Suppl):2732s–2736s.PubMed
34.
Lin DL, Chang C. p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily. J Biol Chem. 1996;271(25):14649–52.PubMedCrossRef
35.
Kozaki K, Miyaishi O, Tsukamoto T, Tatematsu Y, Hida T, Takahashi T, Takahashi T. Establishment and characterization of a human lung cancer cell line NCI-H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. Cancer Res. 2000;60(9):2535–40.PubMed
36.
Chen YT, Chen Z, Du YN. Immunohistochemical analysis of RHAMM expression in normal and neoplastic human tissues: a cell cycle protein with distinctive expression in mitotic cells and testicular germ cells. Oncotarget. 2018;9(30):20941–52.PubMedPubMedCentralCrossRef
37.
Sohr S, Engeland K. RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53. Cell Cycle. 2008;7(21):3448–60.PubMedCrossRef
38.
Liu H, Dilger JP, Lin J. The role of transient receptor potential melastatin 7 (TRPM7) in cell viability: a potential target to suppress breast cancer cell cycle. Cancers. 2020;12:1.
39.
40.
Wang H, Chen Y, Zhai N, Chen X, Gan F, Li H, Huang K. Ochratoxin A-Induced Apoptosis of IPEC-J2 Cells through ROS-Mediated Mitochondrial Permeability Transition Pore Opening Pathway. J Agric Food Chem. 2017;65(48):04434.CrossRef
41.
Ying H, Xiao Z-XJ. Targeting retinoblastoma protein for degradation by proteasomes. Cell Cycle. 2006;5(5):506–8.PubMedCrossRef
42.
Ma Y, Chen Y, Lin C, Hu G. Biological functions and clinical significance of the newly identified long non–coding RNA RP1–85F186in colorectal cancer. Oncol Rep. 2010;2:4.
43.
Trakala M, Malumbres M. Cyclin C surprises in tumour suppression. Nat Cell Biol. 2014;16(11):1031–3.PubMedCrossRef
44.
Keenan SM, Lents NH, Baldassare JJ. Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression. J Biol Chem. 2004;279(7):5387–96.PubMedCrossRef
45.
Metadata
Title
Emodin regulates cell cycle of non-small lung cancer (NSCLC) cells through hyaluronan synthase 2 (HA2)-HA-CD44/receptor for hyaluronic acid-mediated motility (RHAMM) interaction-dependent signaling pathway
Authors
Mingzhu Li
Shengbo Jin
Yang Cao
Jian Xu
Shendong Zhu
Zheng Li
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01711-z

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Review

Small ring has big potential: insights into extrachromosomal DNA in cancer

Primary research

Knockdown of POLQ interferes the development and progression of hepatocellular carcinoma through regulating cell proliferation, apoptosis and migration

Primary research

Deregulation of angiopoietin-like 4 slows ovarian cancer progression through vascular endothelial growth factor receptor 2 phosphorylation

Primary research

Prognostic and predictive value of FCER1G in glioma outcomes and response to immunotherapy

Primary research

Metapristone (RU486-derivative) inhibits endometrial cancer cell progress through regulating miR-492/Klf5/Nrf1 axis

Primary research

Echinacoside exerts anti-tumor activity via the miR-503-3p/TGF-β1/Smad aixs in liver cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits